Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Periscope-06 perioperative trastuzumab rezetecan + trastuzumab + sintilimab in locally advanced HER2-positive gastric/GEJ adenocarcinoma
ChiCTR2600135376Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Oct 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab rezetecan, trastuzumab and sintilimab in gastric cancer (GC) and gastroesophageal junction adenocarcinoma, sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Pathological complete response rate. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2600135376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600135376.